Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gD1-306-HD is a preclinical liposomal vaccine candidate developed by Molecular Express for the prevention or treatment of Herpes Simplex Virus Type 2 (HSV-2) infection. Utilizing the company's proprietary VesiVax platform, the vaccine consists of a truncated HSV-2 glycoprotein D (gD) ectodomain antigen (residues 1-306) formulated within a liposomal delivery system that incorporates an adjuvant. The mechanism of action involves the presentation of the gD antigen to the immune system to elicit a robust neutralizing antibody and T-cell response against HSV-2. The VesiVax platform is designed to enhance the delivery of both the antigen and the adjuvant, potentially improving the immunogenicity and protective efficacy of the vaccine compared to traditional formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gD1-306-HD.